Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s ...
Supernus: Q4 Earnings Snapshot
The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 52 cents per share. The drugmaker posted revenue of $174.2 million in the period, which also beat ...
Supernus Pharmaceuticals Q4 revenue beats, EPS misses estimates
The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...
Supernus reports Q4 EPS 27c, consensus 52c
Reports Q4 revenue $174.2M, consensus $155.25M. “Our 2024 results reflect solid commercial execution across the company, including continued ...
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...
pharmaphorum23h
Supernus bulks up its Parkinson's portfolio with Adamas takeover
Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable.